Achaogen is a biopharmaceutical company engaged in discovering, developing, and commercializing antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. Co. develops plazomicin for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Co. also develops antibacterial candidate, C-Scape, an orally-administered combination of ceftibuten and clavulanate for oral treatment for patients with cUTI, and acute pyelonephritis, caused by expanded spectrum beta-lactamases-producing Enterobacteriaceae. We show 21 historical shares outstanding datapoints in our coverage of AKAO's shares outstanding history.
Understanding the changing numbers of AKAO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AKAO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AKAO by allowing them to research AKAO shares outstanding history
as well as any other stock in our coverage universe. |
Free AKAO Email Alerts:
Video: Shares Outstanding Importance
